Melatonin alleviates intervertebral disc degeneration by disrupting the IL-1β/NF-κB-NLRP3 inflammasome positive feedback loop

Abstract

The inflammatory response is induced by the overexpression of inflammatory cytokines, mainly interleukin (IL)-1β, and is one of the main causes of intervertebral disc degeneration (IVDD). NLR pyrin domain containing 3 (NLRP3) inflammasome activation is an important source of IL-1β. As an anti-inflammatory neuroendocrine hormone, melatonin plays various roles in different pathophysiological conditions. However, its roles in IVDD are still not well understood and require more examination. First, we demonstrated that melatonin delayed the progression of IVDD and relieved IVDD-related low back pain in a rat needle puncture IVDD model; moreover, NLRP3 inflammasome activation (NLRP3, p20, and IL-1β levels) was significantly upregulated in severely degenerated human discs and a rat IVDD model. Subsequently, an IL-1β/NF-κB-NLRP3 inflammasome activation positive feedback loop was found in nucleus pulposus (NP) cells that were treated with IL-1β. In these cells, expression of NLRP3 and p20 was significantly increased, NF-κB signaling was involved in this regulation, and mitochondrial reactive oxygen species (mtROS) production increased. Furthermore, we found that melatonin disrupted the IL-1β/NF-κB-NLRP3 inflammasome activation positive feedback loop in vitro and in vivo. Melatonin treatment decreased NLRP3, p20, and IL-1β levels by inhibiting NF-κB signaling and downregulating mtROS production. Finally, we showed that melatonin mediated the disruption of the positive feedback loop of IL-1β in vivo. In this study, we showed for the first time that IL-1β promotes its own expression by upregulating NLRP3 inflammasome activation. Furthermore, melatonin disrupts the IL-1β positive feedback loop and may be a potential therapeutic agent for IVDD.

References

[1] Vlaeyen, J. W. S. et al. Low back pain. Nat. Rev. Dis. Primers 4, 52 (2018).

[2] Hoy D, Brooks P, Blyth F, Buchbinder R. The epidemiology of low back pain. Best. Pract. Res. Clin. Rheumatol., 2010, 24:769-781

[3] Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet, 2017, 389:736-747

[4] Hoy D et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann. Rheum. Dis., 2014, 73:968-974

[5] Yang G et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet, 2013, 381:1987-2015

[6] Foster NE et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet, 2018, 391:2368-2383

[7] Hartvigsen J et al. What low back pain is and why we need to pay attention. Lancet, 2018, 391:2356-2367

[8] Silagi ES, Shapiro IM, Risbud MV. Glycosaminoglycan synthesis in the nucleus pulposus: Dysregulation and the pathogenesis of disc degeneration. Matrix Biol., 2018, 71–72:368-379

[9] Roughley PJ. Biology of intervertebral disc aging and degeneration: involvement of the extracellular matrix. Spine, 2004, 29:2691-2699

[10] Ding F, Shao ZW, Xiong LM. Cell death in intervertebral disc degeneration. Apoptosis, 2013, 18:777-785

[11] Zhao CQ, Jiang LS, Dai LY. Programmed cell death in intervertebral disc degeneration. Apoptosis, 2006, 11:2079-2088

[12] Ji ML et al. Preclinical development of a microRNA-based therapy for intervertebral disc degeneration. Nat. Commun., 2018, 9

[13] Adams MA, Dolan P, McNally DS. The internal mechanical functioning of intervertebral discs and articular cartilage, and its relevance to matrix biology. Matrix Biol., 2009, 28:384-389

[14] Roberts S, Evans H, Trivedi J, Menage J. Histology and pathology of the human intervertebral disc. J. Bone Jt. Surg. Am. Vol., 2006, 88 Suppl 2 10-14

[15] Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. Nat. Rev. Rheumatol., 2014, 10:44-56

[16] Yang W et al. Interleukin-1beta in intervertebral disk degeneration. Clin. Chim. Acta, 2015, 450:262-272

[17] de Zoete MR, Palm NW, Zhu S, Flavell RA. Inflammasomes. Cold Spring Harb. Perspect. Biol., 2014, 6:a016287

[18] He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci., 2016, 41:1012-1021

[19] Próchnicki Tomasz, Mangan Matthew S., Latz Eicke. Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation. F1000Research, 2016, 5:1469

[20] Freeman LC, Ting JP. The pathogenic role of the inflammasome in neurodegenerative diseases. J. Neurochem., 2016, 136 Suppl 1 29-38

[21] Heneka MT, McManus RM, Latz E. Inflammasome signalling in brain function and neurodegenerative disease. Nat. Rev. Neurosci., 2018, 19:610-621

[22] McAllister MJ, Chemaly M, Eakin AJ, Gibson DS, McGilligan VE. NLRP3 as a potentially novel biomarker for the management of osteoarthritis. Osteoarthr. Cartil., 2018, 26:612-619

[23] Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol. Cancer, 2018, 17

[24] Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol. Res., 2017, 5:94-99

[25] Mangan MSJ et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov., 2018, 17:588-606

[26] Mao L, Kitani A, Strober W, Fuss IJ. The role of NLRP3 and IL-1beta in the pathogenesis of inflammatory bowel disease. Front. Immunol., 2018, 9:2566

[27] Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Arthritis Res. Ther., 2005, 7:R732-R745

[28] Acuna-Castroviejo D et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell. Mol. life Sci., 2014, 71:2997-3025

[29] Venegas C et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J. Pineal Res., 2012, 52:217-227

[30] Favero G, Franceschetti L, Bonomini F, Rodella LF, Rezzani R. Melatonin as an anti-inflammatory agent modulating inflammasome activation. Int. J. Endocrinol., 2017, 2017:1835195

[31] Hardeland R. Melatonin and inflammation-story of a double-edged blade. J. Pineal Res., 2018, 65

[32] Sarlak G, Jenwitheesuk A, Chetsawang B, Govitrapong P. Effects of melatonin on nervous system aging: neurogenesis and neurodegeneration. J. Pharmacol. Sci., 2013, 123:9-24

[33] Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol. Sin., 2006, 27:41-49

[34] Karaaslan C, Suzen S. Antioxidant properties of melatonin and its potential action in diseases. Curr. Top. Med. Chem., 2015, 15:894-903

[35] Ganie SA et al. Melatonin: a potential anti-oxidant therapeutic agent for mitochondrial dysfunctions and related disorders. Rejuvenation Res., 2016, 19:21-40

[36] Giannoulia-Karantana A, Vlachou A, Polychronopoulou S, Papassotiriou I, Chrousos GP. Melatonin and immunomodulation: connections and potential clinical applications. Neuroimmunomodulation, 2006, 13:133-144

[37] Calvo JR, Rafii-el-Idrissi M, Pozo D, Guerrero JM. Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. J. Pineal Res., 1995, 18:119-126

[38] Poza, J. J., Pujol, M., Ortega-Albas, J. J. & Romero, O. Melatonin in sleep disorders. Neurologia. https://doi.org/10.1016/j.nrl.2018.08.002 (2018).

[39] Talib Wamidh. Melatonin and Cancer Hallmarks. Molecules, 2018, 23 3 518

[40] Su Shih-Chi, Hsieh Ming-Ju, Yang Wei-En, Chung Wen-Hung, Reiter Russel J., Yang Shun-Fa. Cancer metastasis: Mechanisms of inhibition by melatonin. Journal of Pineal Research, 2016, 62 1 e12370

[41] Reiter Russel, Rosales-Corral Sergio, Tan Dun-Xian, Acuna-Castroviejo Dario, Qin Lilan, Yang Shun-Fa, Xu Kexin. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. International Journal of Molecular Sciences, 2017, 18 4 843

[42] Farhood Bagher, Goradel Nasser Hashemi, Mortezaee Keywan, Khanlarkhani Neda, Najafi Masoud, Sahebkar Amirhossein. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. Journal of Cellular Physiology, 2018, 234 5 5613-5627

[43] Ma S et al. Melatonin ameliorates the progression of atherosclerosis via mitophagy activation and NLRP3 inflammasome inhibition. Oxid. Med. Cell. Longev., 2018, 2018:9286458

[44] Dong Y et al. Melatonin attenuated early brain injury induced by subarachnoid hemorrhage via regulating NLRP3 inflammasome and apoptosis signaling. J. Pineal Res., 2016, 60:253-262

[45] Cao Zhengwang, Fang Yiliang, Lu Yonghui, Tan Dunxian, Du Changhong, Li Yuming, Ma Qinlong, Yu Junmei, Chen Mengyan, Zhou Chao, Pei Liping, Zhang Lei, Ran Haiying, He Mindi, Yu Zhengping, Zhou Zhou. Melatonin alleviates cadmium-induced liver injury by inhibiting the TXNIP-NLRP3 inflammasome. Journal of Pineal Research, 2017, 62 3 e12389

[46] Zhang Y et al. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J. Pineal Res., 2016, 60:405-414

[47] Li Zheng, Li Xingye, Chen Chong, Chan Matthew T. V., Wu William Ka Kei, Shen Jianxiong. Melatonin inhibits nucleus pulposus (NP) cell proliferation and extracellular matrix (ECM) remodeling via the melatonin membrane receptors mediated PI3K-Akt pathway. Journal of Pineal Research, 2017, 63 3 e12435

[48] Zhang Zengjie, Lin Jialiang, Tian Naifeng, Wu Yaosen, Zhou Yifei, Wang Chenggui, Wang Qingqing, Jin Haiming, Chen Tingting, Nisar Majid, Zheng Gang, Xu Tianzhen, Gao Weiyang, Zhang Xiaolei, Wang Xiangyang. Melatonin protects vertebral endplate chondrocytes against apoptosis and calcification via the Sirt1-autophagy pathway. Journal of Cellular and Molecular Medicine, 2018, 23 1 177-193

[49] He R et al. Melatonin resists oxidative stress-induced apoptosis in nucleus pulposus cells. Life Sci., 2018, 199:122-130

[50] Tian Y et al. Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-kappaB. Am. J. Pathol., 2013, 182:2310-2321

[51] Wang J et al. Tumor necrosis factor alpha- and interleukin-1beta-dependent induction of CCL3 expression by nucleus pulposus cells promotes macrophage migration through CCR1. Arthritis Rheum., 2013, 65:832-842

[52] Shi Q et al. Mitochondrial ROS activate interleukin-1beta expression in allergic rhinitis. Oncol. Lett., 2018, 16:3193-3200

[53] Oh JY et al. Mesenchymal stem/stromal cells inhibit the NLRP3 inflammasome by decreasing mitochondrial reactive oxygen species. Stem Cells, 2014, 32:1553-1563

[54] Dolunay A et al. Inhibition of NLRP3 inflammasome prevents LPS-induced inflammatory hyperalgesia in mice: contribution of NF-kappaB, Caspase-1/11, ASC, NOX, and NOS isoforms. Inflammation, 2017, 40:366-386

[55] Zheng Q et al. Hyperosmotic stress-induced TRPM2 channel activation stimulates NLRP3 inflammasome activity in primary human corneal epithelial cells. Investig. Ophthalmol. Vis. Sci., 2018, 59:3259-3268

[56] Tang P et al. Honokiol alleviates the degeneration of intervertebral disc via suppressing the activation of TXNIP-NLRP3 inflammasome signal pathway. Free Radic. Biol. Med., 2018, 120:368-379

[57] Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat. Rev. Immunology, 2010, 10:210-215

[58] Mezzasoma L, Antognelli C, Talesa VN. A novel role for brain natriuretic peptide: inhibition of IL-1beta secretion via downregulation of NF-kB/Erk 1/2 and NALP3/ASC/Caspase-1 activation in human THP-1 monocyte. Mediators Inflamm., 2017, 2017:5858315

[59] Yu X et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1beta production via suppressing the NF-kappaB pathway and ROS production. J. Hepatol., 2017, 66:693-702

[60] Budai MM, Varga A, Milesz S, Tozser J, Benko S. Aloe vera downregulates LPS-induced inflammatory cytokine production and expression of NLRP3 inflammasome in human macrophages. Mol. Immunol., 2013, 56:471-479

[61] Human Experimentation. Code of ethics of the world medical association (Declaration of Helsinki). Can. Med. Assoc. J., 1964, 91:619

[62] Zhang Jian, Wang Xiaolin, Liu Hui, Li Zemin, Chen Fan, Wang Hua, Zheng Zhaomin, Wang Jianru. TNF‐α enhances apoptosis by promoting chop expression in nucleus pulposus cells: role of the MAPK and NF‐κB pathways. Journal of Orthopaedic Research, 2019, 37 3 697-705

[63] Zhang J et al. TGF-beta1 suppresses CCL3/4 expression through the ERK signaling pathway and inhibits intervertebral disc degeneration and inflammation-related pain in a rat model. Exp. Mol. Med., 2017, 49

[64] Li Z et al. Both expression of cytokines and posterior annulus fibrosus rupture are essential for pain behavior changes induced by degenerative intervertebral disc: an experimental study in rats. J. Orthop. Res., 2014, 32:262-272

[65] Li Z et al. Wnt5a suppresses inflammation-driven intervertebral disc degeneration via a TNF-alpha/NF-kappaB-Wnt5a negative-feedback loop. Osteoarthr. Cartil., 2018, 26:966-977

[66] Singh K, Masuda K, An HS. Animal models for human disc degeneration. Spine J., 2005, 5:267s-279s

[67] Chen D et al. Metformin protects against apoptosis and senescence in nucleus pulposus cells and ameliorates disc degeneration in vivo. Cell Death Dis., 2016, 7

Funding

National Natural Science Foundation of China (National Science Foundation of China)(81572175)

Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation)(2017A030313670)